Severe or life-threatening events occur in up to 55% of patients receiving dual-agent regimens [3]. Among endocrine irAEs, thyroiditis is most commonly linked to PD-1 inhibitors [1,2,4], while hypophysitis is more frequently associated with CTLA-4 blockade [1,2,5]. This evidence concerns the gene PDCD1 and hypophysitis.